Healthcare Jan 27, 2022 10:13 AM (GMT+8) · EqualOcean
On January 26, 2022, immunocore announced that tebentafusp was approved by FDA for the treatment of HLA-A * 02:01 genotype, metastatic or unresectable uveal melanoma, with the trade name of kimmtrak. The press release pointed out that the approval set several firsts: it is the first FDA approved treatment for unresectable or metastatic uveal melanoma. It is also the first regulatory approved T cell receptor (TCR) therapy and the first FDA approved bispecific T cell connector for the treatment of solid tumors.